The US health authorities have approved a new antibiotic to treat urinary tract infections, a medical problem that affects more than 100 million people a year worldwide, mainly women.
British Pharmaceutical Gelcio GSK announced on Tuesday, March 26 that it received the green light of the American Medicines Agency (FDA) to market this new treatment called Blujepa in the United States.
“A crucial step,” according to Tony Wood, GSK’s scientific director, because it is “the first of a new class of oral antibiotics for urinary tract infections” that will be approved “for almost three decades.”
“Offer another option to patients”
If there are already other antibiotics in the market and allow these infections to be treated, the arrival of a new treatment should allow “another option for patients with recurrent infections and facing increasing resistance to existing treatments,” explains Tony Wood.
Repeated use of antibiotics has contributed to the appearance of increasingly resistant bacteria, which causes infections to cause more and more difficult to treat.
According to a study published in 2019, more than 92% of the bacteria responsible for urinary tract infections are resistant to at least one antibiotic, and almost 80% of them are resistant to at least two.
Blujepa can be prescribed to women and girls over 12 years old and suffer a simple urinary tract infection, GSK said.
Source: BFM TV
